Detalhe da pesquisa
1.
Predicting immunotherapy outcomes in patients with MSI tumors using NLR and CT global tumor volume.
Front Oncol
; 12: 982790, 2022.
Artigo
em Inglês
| MEDLINE | ID: mdl-36387101
2.
Overcoming resistance to αPD-1 of MMR-deficient tumors with high tumor-induced neutrophils levels by combination of αCTLA-4 and αPD-1 blockers.
J Immunother Cancer
; 10(7)2022 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-35896284
3.
Association of the Lung Immune Prognostic Index with Immunotherapy Outcomes in Mismatch Repair Deficient Tumors.
Cancers (Basel)
; 13(15)2021 Jul 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-34359675
4.
Systemic short chain fatty acids limit antitumor effect of CTLA-4 blockade in hosts with cancer.
Nat Commun
; 11(1): 2168, 2020 05 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-32358520
5.
Why is immunotherapy effective (or not) in patients with MSI/MMRD tumors?
Bull Cancer
; 106(2): 105-113, 2019 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-30342749
6.
Hypermutated tumours in the era of immunotherapy: The paradigm of personalised medicine.
Eur J Cancer
; 84: 290-303, 2017 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-28846956